Arcellx ACLX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Arcellx (ACLX) Business Model and Operations Summary
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Key Insights
Arcellx (ACLX) Core Market Data and Business Metrics
Latest Closing Price
$60.7Market Cap
$3.34 BillionPrice-Earnings Ratio
-85.49Total Outstanding Shares
54.94 Million SharesTotal Employees
163Dividend
No dividendIPO Date
February 4, 2022SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
800 Bridge Parkway, Redwood City, CA, 94065
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-157.91 Million |
| Net Cash Flow From Operating Activities, Continuing | $20.81 Million |
| Net Cash Flow, Continuing | $33.42 Million |
| Net Cash Flow | $33.42 Million |
| Net Cash Flow From Investing Activities | $-157.91 Million |
| Net Cash Flow From Operating Activities | $20.81 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Income/Loss From Continuing Operations Before Tax | $-39.24 Million |
| Income Tax Expense/Benefit | $1.19 Million |
| Net Income/Loss Attributable To Parent | $-40.42 Million |
| Operating Income/Loss | $-69.42 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-40.42 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-38.46 Million |
| Comprehensive Income/Loss | $-38.46 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-38.46 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Parent | $483.02 Million |
| Current Liabilities | $137.02 Million |
| Assets | $764.91 Million |
| Current Assets | $587.30 Million |
| Fixed Assets | $47.50 Million |
| Noncurrent Liabilities | $144.87 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||